Physician profile
Christopher James Whitty
NPI 1457339574
$6,082.37
in general payments reported to CMS, 2019-2025
44 companies · $1,379 in 2025
The $1,379 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $891 · 2020: $334 · 2021: $639 · 2022: $836 · 2023: $712 · 2024: $1,292 · 2025: $1,379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,383.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $682.53 | 2019-2025 | Nayzilam, Briviact, Rystiggo |
| Abbvie INC. | $604.48 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Biogen, INC. | $454.62 | 2019-2025 | Vumerity, Avonex, Tysabri |
| Amneal Pharmaceuticals LLC | $430.58 | 2019-2025 | Crexont, Rytary |
| Mdd US Operations, LLC | $423.77 | 2019-2025 | Apokyn, Apokyn |
| Pfizer INC. | $333.17 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $284.04 | 2019-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $244.65 | 2021-2025 | Ingrezza, Ongentys |
| Novartis Pharmaceuticals Corporation | $218.80 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $206.90 | 2024-2025 | Purified Cortrophin Gel |
| Genzyme Corporation | $192.91 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $191.05 | 2019-2024 | Austedo Xr, Ajovy, Austedo |
| Allergan, INC. | $174.14 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $169.80 | 2021-2025 | Wainua, Andexxa |
| Eisai INC. | $162.45 | 2019-2025 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Whitty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.